Blood VEGF level-lowering agent containing IL-6 antagonist as the active ingredient

• US 20070243189A1
• Filed: 06/18/2007
• Published: 10/18/2007
• Est. Priority Date: 10/27/2000
• Status: Active Grant

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Yoshizaki, Kazuyuki, Nishimoto, Norihiro
• Granted Patent: US 8,173,126 B2
• Time in Patent Office: Days
• US Class Current: 424/133.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons

Abstract

A blood vascular endothelial growth factor (VEGF) level-lowering agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Claims

1-24. -24. (canceled)

25. A method for lowering blood vascular endothelial growth factor (VEGF) level, comprising administering to a patient in need thereof an antibody against interleukin-6 (IL-6) in an amount effective to inhibit angiogenesis.

27. The method according to claims 25 or 26, wherein the antibody against IL-6 or IL-6 receptor is a monoclonal antibody against IL-6 or IL-6 receptor.

28. The method according to claim 27, in which the monoclonal antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

29. The method according to claim 27, in which the monoclonal antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

31. The method according to claim 28, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

32. The method according to claim 29, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

26. A method for lowering blood VEGF level, comprising administering to a patient in need thereof an antibody against IL-6 receptor in an amount effective to inhibit angiogenesis.

30. The method according to claim 26, in which the antibody against IL-6 receptor is a recombinant antibody.

33. The method according to claim 26, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

34. The method according to claim 33, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.

35. A method for inhibiting angiogenesis, comprising administering to a patient in need thereof an antibody against interleukin-6 (IL-6) in an amount effective to inhibit angiogenesis.

36. A method for inhibiting angiogenesis, comprising administering to a patient in need thereof an antibody against IL-6 receptor in an amount effective to inhibit angiogenesis.

37. The method according to claim 36, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

38. The method according to claim 37, in which the monoclonal antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

39. The method according to claim 37, in which the monoclonal antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

40. The method according to claim 36, in which the antibody against IL-6 receptor is a recombinant antibody.

41. The method according to claim 38, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

42. The method according to claim 39, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

43. The method according to claim 36, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

44. The method according to claim 43, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.